drugset
drugset / Trial / NCT00965419

A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder

NCT00965419 ↗

Phase 2/3 Terminated 267 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).

Timeline

Start
2009-09
Primary completion
2015-07
Completion
2015-07

Outcome

Outcome not reported

Stopped: “Terminated due to low 5 year completer number and not meeting primary objective.”

Drugs

EvaluationDrugModalityDoseRoute
Subject edivoxetine Small molecule 0.1 mg/kg Oral
Subject edivoxetine Small molecule 0.3 mg/kg Oral

Indications

attention deficit-hyperactivity disorder